1-5 of 5
Gilles Favre
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

Olivier Calvayrac, Anne Pradines, Isabelle Raymond-Letron, Isabelle Rouquette, Emilie Bousquet, Valérie Lauwers-Cances, Thomas Filleron, Jacques Cadranel, Michèle Beau-Faller, Anne Casanova, Julie Milia, Gilles Favre, Julien Mazières
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6541–6550.
https://doi.org/10.1158/1078-0432.CCR-14-0506
Published: 14 December 2014
View article titled, RhoB Determines Tumor Aggressiveness in a Murine EGFR<sup>L858R</sup>-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Open the PDF for RhoB Determines Tumor Aggressiveness in a Murine EGFR<sup>L858R</sup>-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B17: The small RhoGTPase RhoB as a new potential marker of EGFR-TKI resistance

Claire Marty, Gilles Favre, Julien Mazieres
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): B17.
https://doi.org/10.1158/1078-0432.12AACRIASLC-B17
Published: 01 February 2012
View article titled, Abstract B17: The small RhoGTPase RhoB as a new potential marker of EGFR-TKI resistance
Open the PDF for Abstract B17: The small RhoGTPase RhoB as a new potential marker of EGFR-TKI resistance in another window
Journal Articles

Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis

Florence Dalenc, Sophie F. Doisneau-Sixou, Ben C. Allal, Sabrina Marsili, Valérie Lauwers-Cances, Karima Chaoui, Odile Schiltz, Bernard Monsarrat, Thomas Filleron, Nicole Renée, Emilie Malissein, Elise Meunier, Gilles Favre, Henri Roché
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1264–1271.
https://doi.org/10.1158/1078-0432.CCR-09-1192
Published: 15 February 2010
View article titled, Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis
Open the PDF for Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis in another window
Includes: Supplementary data
Journal Articles

Loss of RhoB Expression in Human Lung Cancer Progression

Julien Mazieres, Teresita Antonia, Ghislaine Daste, Carlos Muro-Cacho, Delphine Berchery, Vanessa Tillement, Anne Pradines, Said Sebti, Gilles Favre
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (8): 2742–2750.
https://doi.org/10.1158/1078-0432.CCR-03-0149
Published: 20 April 2004
View article titled, Loss of RhoB Expression in Human Lung Cancer Progression
Open the PDF for Loss of RhoB Expression in Human Lung Cancer Progression in another window
Journal Articles

The Farnesyltransferase Inhibitor R115777 Reduces Hypoxia and Matrix Metalloproteinase 2 Expression in Human Glioma Xenograft

Caroline Delmas, Dave End, Philippe Rochaix, Gilles Favre, Christine Toulas, Elizabeth Cohen-Jonathan
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 6062–6068.
Published: 15 December 2003
View article titled, The Farnesyltransferase Inhibitor R115777 Reduces Hypoxia and Matrix Metalloproteinase 2 Expression in Human Glioma Xenograft
Open the PDF for The Farnesyltransferase Inhibitor R115777 Reduces Hypoxia and Matrix Metalloproteinase 2 Expression in Human Glioma Xenograft in another window